PL3700546T3 - Peptydy wnt5a do zmniejszania liczby nowotworowych komórek macierzystych - Google Patents

Peptydy wnt5a do zmniejszania liczby nowotworowych komórek macierzystych

Info

Publication number
PL3700546T3
PL3700546T3 PL18789182.5T PL18789182T PL3700546T3 PL 3700546 T3 PL3700546 T3 PL 3700546T3 PL 18789182 T PL18789182 T PL 18789182T PL 3700546 T3 PL3700546 T3 PL 3700546T3
Authority
PL
Poland
Prior art keywords
wnt5a
peptides
reduction
stem cells
cancer stem
Prior art date
Application number
PL18789182.5T
Other languages
English (en)
Inventor
Anita SJÖLANDER
Original Assignee
Wntresearch Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wntresearch Ab filed Critical Wntresearch Ab
Publication of PL3700546T3 publication Critical patent/PL3700546T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
PL18789182.5T 2017-10-25 2018-10-25 Peptydy wnt5a do zmniejszania liczby nowotworowych komórek macierzystych PL3700546T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17198369 2017-10-25
PCT/EP2018/079319 WO2019081657A1 (en) 2017-10-25 2018-10-25 WNT5A PEPTIDES FOR REDUCING CANCER STEM CELLS

Publications (1)

Publication Number Publication Date
PL3700546T3 true PL3700546T3 (pl) 2024-03-11

Family

ID=60190627

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18789182.5T PL3700546T3 (pl) 2017-10-25 2018-10-25 Peptydy wnt5a do zmniejszania liczby nowotworowych komórek macierzystych

Country Status (10)

Country Link
US (1) US20210008149A1 (pl)
EP (2) EP3700546B1 (pl)
JP (2) JP2021500415A (pl)
KR (1) KR20200076713A (pl)
CN (1) CN111417403B (pl)
CA (1) CA3080256A1 (pl)
ES (1) ES2963914T3 (pl)
PL (1) PL3700546T3 (pl)
SG (1) SG11202003613YA (pl)
WO (1) WO2019081657A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3222037A1 (en) * 2021-06-01 2022-12-08 Wntresearch Ab Wnt5a peptides for the treatment of acute myelogenous leukemia
WO2024038051A1 (en) * 2022-08-15 2024-02-22 Wntresearch Ab Prevention of tumour proliferation and growth

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543473T3 (es) * 2005-05-30 2015-08-19 Wntresearch Ab Un ligando peptídico para alterar la migración de células cancerígenas
WO2009134204A1 (en) * 2008-04-30 2009-11-05 Forskarpatent I Syd Ab RESTORATION OF ESTROGEN RECEPTOR-α ACTIVITY
EP2726880B1 (en) * 2011-07-01 2019-04-17 Wntresearch AB Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients
JP6921755B2 (ja) * 2014-12-10 2021-08-18 ハイパーステム ソシエテ アノニム 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物

Also Published As

Publication number Publication date
KR20200076713A (ko) 2020-06-29
CN111417403A (zh) 2020-07-14
SG11202003613YA (en) 2020-05-28
US20210008149A1 (en) 2021-01-14
CA3080256A1 (en) 2019-05-02
ES2963914T3 (es) 2024-04-03
JP2021500415A (ja) 2021-01-07
EP3700546B1 (en) 2023-08-16
CN111417403B (zh) 2024-06-04
EP3700546A1 (en) 2020-09-02
EP3700546C0 (en) 2023-08-16
EP4154902A1 (en) 2023-03-29
WO2019081657A1 (en) 2019-05-02
JP2023156343A (ja) 2023-10-24

Similar Documents

Publication Publication Date Title
HRP20210709T8 (hr) Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma
SG10202003124TA (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
SI3430027T1 (sl) Peptid za uporabo v imunoterapiji proti nedrobnoceličnemu pljučnemu raku in drobnoceličnemu pljučnemu raku
HUE054453T2 (hu) Új peptidek és peptidkombinációk az emlõrák és más ráktípusok elleni immunterápiában történõ használatra
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
IL261786A (en) Peptides and a combination of peptides for use in immunotherapy against types of cancer
GB201613078D0 (en) Stem cells and cancer
EP3420075A4 (en) PRODUCTION OF CANCER STEM CELLS AND USE THEREOF
EP3111951A4 (en) Anticancer functional peptide for inhibiting proliferation of cancer stem cell, and use thereof
SG11202005509YA (en) Recombinant adenoviruses and stem cells comprising same
HK1255541A1 (zh) 用於多種癌症免疫治療的新型肽和肽組合物
GB201716408D0 (en) Stem cell microparticles for cancer therapy
ZA201901942B (en) Nnif and nnif-related peptides and related methods
SG11202003613YA (en) Wnt5a peptides in reduction of cancer stem cells
EP3480212C0 (en) IL13RALPHA2 PEPTIDE AND ITS USES
HK1258386A1 (zh) 用於小細胞肺癌和其他癌症免疫治療的肽和肽組合物
IL262081A (en) New peptides and combinations of peptides for use in immunotherapy for the treatment of acute myeloid leukemia and other cancers
HK1212920A1 (zh) 使用麥膠蛋白肽治療癌症的套件和方法
EP3247801A4 (en) Ribosome-mediated incorporation of peptides and peptidomimetics